State-of-the-Art ReviewAssessment of Vascular Dysfunction in Patients Without Obstructive Coronary Artery Disease: Why, How, and When
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
Dr. Pepine is supported by the National Heart, Lung, and Blood Institute (NHLBI) (R01 HL146158, R01 HL 132448, R01 HL091005, U01 HL064924, U01 HL087366, UM1 HL087366, UM1 HL087366, and UM1 HL087364), the National Institutes of Health (NIH)/National Center for Advancing Translational Sciences (UL1 TR001427), the U.S. Department of Defense (W81XWH1720030 and W81XWH-17-2-0030), NIH/Brigham and Women’s Hospital (5U01 HL130163-02), GE Healthcare (GE-265-303), Merck (MK-1242-001-01), Sanofi (EFC11570), the University of Florida Office of Research (AGR DTD 04-26-2018), CSL Behring (CSL112-3001), BioCardia (BC-14-001-02), Mesoblast (MSB-MPC-CHF001), Ventrix, Athersys, AMI MultiStem, Verily Life Sciences (Project Baseline OSMB), Imbria Pharmaceuticals (Ironwood MSB-MPC-CHF00-DMC), Milestone Pharmaceuticals, Caladrius Biosciences, the Gatorade Trust, and the McJunkin Family Foundation. Dr. Merz has received an unrestricted research grant from Gilead Sciences; has contracts from the NHLBI (N01-HV-68161, N01-HV-68162, N01-HV-68163, and N01-HV-68164); is supported by the National Institute on Aging (U0164829, U01 HL649141, U01 HL649241, K23HL105787, T32HL69751, R01 HL090957, and 1R03AG032631), the National Center for Research Resources (General Clinical Research Center grant MO1-RR00425), the National Center for Advancing Translational Sciences (UL1TR000124), the Edythe L. Broad and Constance Austin Women’s Heart Research Fellowships (Cedars-Sinai Medical Center [CSMC]), the Barbra Streisand Women’s Cardiovascular Research and Education Program (CSMC), the Erika Glazer Women’s Heart Health Project, the California Institute for Precision Medicine and the Adelson Family Foundation (CSMC); has received consulting fees from Medscape (paid to CSMC), Sanofi Vascular (paid to CSMC), NIH and NIH Office of Research on Women’s Health (paid to CSMC), iRhythm, Caladrius (paid to CSMC), and Abbott Diagnostics. Dr. Shimokawa has received support from the Japan Heart Foundation and the Japan Society for Promotion of Science. Dr. Berry is employed by the University of Glasgow, which holds consultancy and/or research agreements with companies that have commercial interests in the diagnosis and treatment of ischemic heart disease, including Abbott Vascular, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, HeartFlow, Menarini Farmaceutica, Opsens, Philips, and Siemens Healthcare; and has received research support from the British Heart Foundation (PG/17/2532884, FS/17/26/32744, and RE/18/6134217) and the Medical Research Council (MR/S005714/1). Dr. Camici is a consultant for Servier; and has received speaker fees from Abbott Vascular. Dr. Ford has acted as a speaker for Abbott Vascular, Boehringer Ingelheim, and Novartis. Dr. Kaski has acted as a speaker for Menarini Farmaceutica and Bayer UK. Drs. Ong and Sechtem have received funding from the Berthold-Leibinger-Foundation; and have received speaking honoraria from Philips/Volcano, Pfizer, and Bayer Healthcare. Dr. Crea has received personal fees from Biotronic, Amgen, AstraZeneca, Servier, Menarini Farmaceutica, and Bristol-Myers Squibb. Dr. Beltrame has received a research grant from AstraZeneca.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Cardiovascular Interventions author instructions page.